The Hawthorne Effect: a randomised, controlled trial

Department of Psychological Medicine, Imperial College London, UK. <>
BMC Medical Research Methodology (Impact Factor: 2.17). 02/2007; 7:30. DOI: 10.1186/1471-2288-7-30
Source: PubMed

ABSTRACT The 'Hawthorne Effect' may be an important factor affecting the generalisability of clinical research to routine practice, but has been little studied. Hawthorne Effects have been reported in previous clinical trials in dementia but to our knowledge, no attempt has been made to quantify them. Our aim was to compare minimal follow-up to intensive follow-up in participants in a placebo controlled trial of Ginkgo biloba for treating mild-moderate dementia.
Participants in a dementia trial were randomised to intensive follow-up (with comprehensive assessment visits at baseline and two, four and six months post randomisation) or minimal follow-up (with an abbreviated assessment at baseline and a full assessment at six months). Our primary outcomes were cognitive functioning (ADAS-Cog) and participant and carer-rated quality of life (QOL-AD).
We recruited 176 participants, mainly through general practices. The main analysis was based on Intention to treat (ITT), with available data. In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group). There was no significant difference on carer quality of life.
We found that more intensive follow-up of individuals in a placebo-controlled clinical trial of Ginkgo biloba for treating mild-moderate dementia resulted in a better outcome than minimal follow-up, as measured by their cognitive functioning.
Current controlled trials: ISRCTN45577048.

Download full-text


Available from: Steve Iliffe, Jun 28, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Routine health information systems (RHISs) are in place in nearly every country and provide routinely collected full-coverage records on all levels of health system service delivery. However, these rich sources of data are regularly overlooked for evaluating causal effects of health programmes due to concerns regarding completeness, timeliness, representativeness and accuracy. Using Mozambique’s national RHIS (Módulo Básico) as an illustrative example, we urge renewed attention to the use of RHIS data for health evaluations. Interventions to improve data quality exist and have been tested in low-and middle-income countries (LMICs). Intrinsic features of RHIS data (numerous repeated observations over extended periods of time, full coverage of health facilities, and numerous real-time indicators of service coverage and utilization) provide for very robust quasi-experimental designs, such as controlled interrupted time-series (cITS), which are not possible with intermittent community sample surveys. In addition, cITS analyses are well suited for continuously evolving development contexts in LMICs by: (1) allowing for measurement and controlling for trends and other patterns before, during and after intervention implementation; (2) facilitating the use of numerous simultaneous control groups and non-equivalent dependent variables at multiple nested levels to increase validity and strength of causal inference; and (3) allowing the integration of continuous ‘effective dose received’ implementation measures. With expanded use of RHIS data for the evaluation of health programmes, investments in data systems, health worker interest in and utilization of RHIS data, as well as data quality will further increase over time. Because RHIS data are ministry-owned and operated, relying upon these data will contribute to sustainable national capacity over time.
    Health Policy and Planning 04/2015; DOI:10.1093/heapol/czv029 · 3.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reductions in risk behaviors are common following enrollment in human immunodeficiency virus (HIV) prevention studies. We develop methods to quantify the proportion of change in risk behaviors that can be attributed to regression to the mean versus study participation and other factors. A novel model that incorporates both regression to the mean and study participation effects is developed for binary measures. The model is used to estimate the proportion of change in the prevalence of "unprotected sex in the past 6 months" that can be attributed to study participation versus regression to the mean in a longitudinal cohort of women at risk for HIV infection who were recruited from ten U.S. communities with high rates of HIV and poverty. HIV risk behaviors were evaluated using audio computer-assisted self-interviews at baseline and every 6 months for up to 12 months. The prevalence of "unprotected sex in the past 6 months" declined from 96% at baseline to 77% at 12 months. However, this change could be almost completely explained by regression to the mean. Analyses that examine changes over time in cohorts selected for high- or low- risk behaviors should account for regression to the mean effects. Copyright © 2015 Elsevier Inc. All rights reserved.
    Annals of epidemiology 03/2015; 25(6). DOI:10.1016/j.annepidem.2015.03.013 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Irritable bowel syndrome is a common diagnosis in gastroenterology. Its aetiology is unknown and therapeutic options limited. Trials suggest that probiotics may be beneficial. The aim of this study was to assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) for the relief of abdominal pain in patients with irritable bowel syndrome fulfilling Rome II criteria. Methods This study was conducted in a referral hospital. Trial participants were randomized to daily receive either two capsules of L. plantarum 299v at a dosage of 5 x 109 c.f.u (colony forming units) per capsule or placebo for 8 weeks. Severity of abdominal pain was assessed with a visual analogue scale at each visit and a quality-of-life irritable bowel syndrome (QoL-IBS) questionnaire was also completed. Trial registration with Clinical NCT01886781. Results There was no significant difference in abdominal pain relief between the study and placebo groups (p = 0.800). There was also no difference in QoL- IBS scores between the groups (p = 0.687). Both the study and placebo groups had a significant improvement in abdominal pain scores over the study period, from an average of 251.55 to 197.90 (p < 0.0001) indicating a large placebo effect. Conclusion An eight week treatment with L. plantarum 299v did not provide symptomatic relief, particularly of abdominal pain and bloating, in patients fulfilling the Rome II criteria.
    Nutrition 10/2014; 30(10). DOI:10.1016/j.nut.2014.02.010 · 3.05 Impact Factor